We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03127098
Recruitment Status : Active, not recruiting
First Posted : April 25, 2017
Last Update Posted : October 5, 2017
Information provided by (Responsible Party):
NantCell, Inc.

Brief Summary:
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred after standard-of-care treatment.

Condition or disease Intervention/treatment Phase
Thyroid Cancer Colon Cancer Ovarian Cancer Breast Cancer Lung Cancer Pancreatic Cancer Biological: ETBX-011 Biological: ALT-803 Phase 1 Phase 2

Detailed Description:
The trial will consist of a phase 1b study with ETBX-011 as a fixed dose with a dose escalation of ALT-803 unless de-escalation is required. The proposed phase 2 expansion study will give additional safety data for the MTD as well as preliminary efficacy data. Subjects will receive treatments unless they experience progressive disease, dose-limiting toxicities (DLT), withdraw consent, or if the investigator determines it is no longer in their best medical interest to continue treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Sequential Assignment
Intervention Model Description: ETBX-011 immunization will be administered by subcutaneous (SC) injection. ALT-803 will be administered by SC injection.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Actual Study Start Date : June 26, 2017
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: ETBX-011 in combination with ALT-803
A combination of agents will be administered to subjects in this dose-escalation study
Biological: ETBX-011
ETBX-011 immunization will be administered by subcutaneous (SC) injection.
Other Name: Ad5 [E1-, E2b-]-CEA(6D)
Biological: ALT-803
ALT-803 will be administered by SC injection.
Other Names:
  • Super-agonist IL-15
  • IL-15

Primary Outcome Measures :
  1. Dose-limiting toxicities and maximum tolerated dose of the ETBX-011 plus ALT-803 combination treatment. (Phase 1b) [ Time Frame: 11 weeks ]
  2. Overall treatment-emergent AEs and SAEs [safety and tolerability] and preliminarily evaluate Objective response rate (ORR). (Phase 2) [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Preliminarily evaluate Duration of Response (DoR) [ Time Frame: 1 year ]
  2. Preliminarily evaluate Progressive-free survival (PFS) [ Time Frame: 1 year ]
  3. Preliminarily evaluate Overall Survival (OS) [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age≥ 21 years.
  2. Subjects with a histologically confirmed diagnosis of locally advanced or metastatic malignancy who were previously treated with at least one method of standard therapy known to have a possible survival benefit or refused such therapy.
  3. The tumor must express CEA or must be known to be universally CEA positive (ie, colon and rectal cancer).
  4. Must have a recent FFPE tumor biopsy specimen.
  5. Subjects who have received prior CEA-targeted immunotherapy (eg, vaccine or antibody) are eligible for this trial if this treatment was discontinued at least 3 months prior to enrollment.
  6. Resolution of all toxic side effects of prior chemotherapy, radiotherapy, or surgical procedures to NCI CTCAE grade ≤ 1.
  7. Ability to understand and provide signed informed consent that fulfills Institutional Review Board (IRB)'s guidelines.
  8. ECOG performance status of 0 or 1.
  9. Subjects who are taking medications that do not have a known history of immunosuppression are eligible for this trial.
  10. Adequate hematologic function at screening, as follows:
  11. WBC count ≥ 3000/microliter.
  12. Hemoglobin ≥ 9 g/dL (may not transfuse or use erythropoietin to achieve this level).
  13. Platelets ≥ 75,000/microliter.
  14. Prothrombin (PT)-international normalized ratio (INR) < 1.5.
  15. Partial thromboplastin time (PTT) < 1.5 × upper limit of normal (ULN).
  16. Adequate renal and hepatic function at screening, as follows:
  17. Serum creatinine < 2.0 mg/dL.
  18. Bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL).
  19. Alanine aminotransferase (ALT) ≤ 2.5 × ULN.
  20. Aspartate aminotransferase (AST) ≤ 2.5 × ULN.
  21. Female subjects of childbearing potential and women < 12 months since the onset of menopause must agree to use acceptable contraceptive methods for the duration of the study and for 7 months following the last injection of study medication. Male subjects must be surgically sterile or must agree to use a condom and acceptable contraceptive method with their partner.
  22. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.

Exclusion Criteria:

  1. Participation in an investigational drug or device study within 30 days of screening for this study.
  2. Pregnant and nursing women.
  3. Subjects with ongoing everolimus or other cancer therapy that interferes with the induction of immune responses.
  4. Subjects with concurrent cytotoxic chemotherapy or radiation therapy. There must be at least one (1) month between any other prior chemotherapy (or radiotherapy) and study treatment. Any prior CEA-targeted immunotherapy (vaccine) must have been discontinued at least 3 months before initiation of study treatment. Subjects must have recovered from all acute toxicities from prior treatment prior to screening for this study.
  5. Active brain or central nervous system metastasis, seizures requiring anticonvulsant treatment, cerebrovascular accident (< 6 months), or transient ischemic attack.
  6. Subjects with a history of autoimmune disease (active or past), such as but not restricted to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune-related thyroid disease and vitiligo are permitted.
  7. Subjects with serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, or other illness considered by the Investigator as high risk for investigational drug treatment.
  8. Subjects with a history of heart disease, such as congestive heart failure (class II, III, or IV defined by the New York Heart Association functional classification), history of unstable or poorly controlled angina, or history (< 1 year) of ventricular arrhythmia.
  9. Subjects with a medical or psychological impediment that would impair the ability of the subject to receive therapy per protocol or impact ability to comply with the protocol or protocol-required visits and procedures.
  10. History of malignancy except for the following: adequately treated non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, or other carcinoma that has been in complete remission without treatment for more than 5 years.
  11. Presence of a known active acute or chronic infection, including human immunodeficiency virus (HIV, as determined by enzyme-linked immunosorbent assay [ELISA] and confirmed by western blot) and hepatitis B and hepatitis C virus (HBV/HCV, as determined by HBsAg and hepatitis C serology).
  12. Subjects on systemic intravenous or oral steroid therapy (or other immunosuppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Subjects must have had at least 6 weeks of discontinuation of any steroid therapy (except that used as premedication for chemotherapy or contrast-enhanced studies) prior to enrollment.
  13. Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded.
  14. Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.
  15. Subjects vaccinated with a live (attenuated) vaccine (e.g., FluMist®) or a killed (inactivated)/subunit vaccine (e.g., PNEUMOVAX®, Fluzone®) within 28 days or 14 days, respectively, of the first planned dose of ETBX-011 or ALT 803.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03127098

United States, Washington
Medical Oncology Associates
Spokane, Washington, United States, 99208
Sponsors and Collaborators
NantCell, Inc.

Responsible Party: NantCell, Inc.
ClinicalTrials.gov Identifier: NCT03127098     History of Changes
Other Study ID Numbers: QUILT-3.040
First Posted: April 25, 2017    Key Record Dates
Last Update Posted: October 5, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by NantCell, Inc.:
locally advanced or metastatic
carcinoembryonic antigen (CEA)-expressing
carcinoembryonic antigen

Additional relevant MeSH terms:
Pancreatic Neoplasms
Thyroid Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Head and Neck Neoplasms
Thyroid Diseases